Meeting: 20th European Symposium on Quantitative Structure-Activity Relationships (EuroQSAR-2014), St. Petersburg

EuroQSAR-2014 will be held in St.-Petersburg, Russia on August 31st - September 4th, 2014. The deadline for oral talks' abstracts submission to the EuroQSAR-2014 is April 23rd, 2014. The meeting, entitled Understanding Chemical-Biological Interactions, will include 9 plenary lectures and 28 oral communications, which will be selected from the submitted abstracts and will focus on:

Chemical-Biological Space: Representation, Visualisation and Navigation.
Chemo- and Bioinformatics Approaches to Multi-Target (Q)SAR.
Modeling of Protein-Ligand Interactions: Structure, Function and Dynamics.
Assessing Ligand Binding Kinetics.
Computational Toxicology in Drug and Chemical Safety Assessment.
Translational Bioinformatics: From Genomes to Drugs.
Emerging QSAR and Modeling Methods.

Two seminars/roundtables are also planned on the last day of the Symposium:

(Q)SAR-Related European Initiatives.
Employing Proper Statistical Approaches for QSAR Modeling and Best Publishing Practices.

Confirmed speakers include:

Opening Lecture - SAR, the Lifelong Learning for my Career Prof. Toshio FUJITA (KYOTO UNIVERSITY, Kyoto, Japan)
From QSAR to MQSPR and Beyond: Predictive Materials Informatics Using a Blend of Heuristic and Physics-Based Methods
Prof. Curt BRENEMAN (RENSSELAER EXPLORATORY CENTER FOR CHEMINFORMATICS RESEARCH, Troy, United States)
Integrating Pharmacometrics into Drug Development Dr Roberta BURSI (GRÜNENTHAL, Aachen, Germany)
Lead Discovery and Optimisation by Use of Interaction Kinetic Analysis Prof. Helena DANIELSON (UPPSALA UNIVERSITY, Uppsala, Sweden)
Navigation in Chemical Space Towards Biological Activity Dr Peter ERTL (NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel,
Switzerland)
Computational Toxicology – An Essential Part of Drug Safety Dr Catrin HASSELGREN (ASTRAZENECA, Mölndal, Sweden)
Ensemble-Based Drug Design, Combining Protein Structures and Simulations Dr Will PITT (UCB PHARMA, Slough, United Kingdom)
The Metabolic Code
Prof. Brian SHOICHET (UNIVERSITY OF TORONTO, Toronto, Canada)
Closing Lecture - Opportunities and Challenges in Therapeutics Discovery and Development Dr John C. REED (F. HOFFMAN-LA-ROCHE, Basel, Switzerland)

Hansch Session

On the Nature of Non-Classical Hydrogen Bonds and Aromatic Interactions Prof. Anna LINUSSON (UMEA UNIVERSITY, Umea, Sweden)
Lessons Learned from the Invention of QSAR Can Inspire Other Breakthrough Discoveries Dr Yvonne C. MARTIN (MARTIN CONSULTING, Waukegan, United States)
The Road Ahead: New Challenges for Computational Forecasts Prof. Tudor I. OPREA (UNIVERSITY OF NEW MEXICO, Albuquerque, United States)
Molecular Design of Bivalent and Dual Action Drugs Prof. Nikolay S. ZEFIROV (MOSCOW STATE UNIVERSITY, Moscow, Russia)

Proceedings of the Symposium will be published in a special issue of the journal Molecular Informatics.

More information you may find at the Symposium’s web-site: www.euroqsar2014.org

Comments

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains: 2,431,025 compounds (of which 2,409,270 have mol files) 3,106,257 compound records (non-unique compounds) 20,772,701 activities 1,644,390 assays 15,598 targets 89,892 documents Data can be downloaded from the ChEMBL FTP site: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and here for a reminder of SureChEMBL is and what it does. This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for local (behind the

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid

The ChEMBL-og

Search This Blog